Neuromuscular disease drugs
These companies develop treatments for inherited muscle diseases, such as Duchenne muscular dystrophy.
+32.3%
over 1 year · S&P 500 +11.6%
Key indicators
Health
50 / 100
Fragile
Solid
Up over 1 year
6 of 12
Volatility
71%
Calm
Choppy
Profitability
−113%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 12 companies
BIIB
+56.9%
SRRK
+40.2%
PTCT
−15.3%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
B
Biogen
BIIB
65.9%
+56.9%
S
Scholar Rock Holding
SRRK
10.0%
+40.2%
P
PTC Therapeutics
PTCT
9.5%
−15.3%
D
Dyne Therapeutics
DYN
6.0%
−7.8%
S
Sarepta Therapeutics
SRPT
3.5%
−10.7%
S
Solid Biosciences
SLDB
1.2%
+44.3%
D
Design Therapeutics
DSGN
1.2%
+37.6%
C
Capricor Therapeutics
CAPR
1.0%
+62.4%
R
REGENXBIO
RGNX
1.0%
−34.1%
T
Entrada Therapeutics
TRDA
0.4%
−36.5%
P
PepGen
PEPG
0.3%
−15.0%
R
Roche Holdings
RHHBY
+21.9%